The new members of Protagen’s Scientific Advisory Board will support the company in the development and implementation of its immuno-profiling technology, with the aim of improving patient selection for novel cancer immunotherapies and offering better management of the risks associated with therapy.

"Protagen feels privileged to bring together the expertise of both Jessica and Aurélien as part of our expanded Scientific Advisory Board. Having dedicated their careers to improving our understanding of cancer and developing new treatment strategies, their extensive knowledge and experience will help to identify how immuno-profiling can advance the prediction of response to immunotherapy and help to avoid immune-related adverse events in cancer patients,” said Dr. Georg Lautscham, CEO at Protagen.

Dr. Hassel (pictured above) commented, “The development of a precision medicine approach for the treatment of different cancers will need to address the challenges posed by limited response rates and irAEs. I am delighted to be able to join Protagen’s Scientific Advisory Board to explore these and other pressing issues with other specialists from around the world.”